Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Increase in curative treatment and survival of lung cancer in Norway 2001-2016.

Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L.

Eur J Epidemiol. 2019 Jul 16. doi: 10.1007/s10654-019-00536-z. [Epub ahead of print]

PMID:
31313073
2.

Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway.

Nilssen Y, Brustugun OT, Tandberg Eriksen M, Gulbrandsen J, Skaaheim Haug E, Naume B, Møller B.

Cancer Epidemiol. 2019 May 27;61:59-69. doi: 10.1016/j.canep.2019.05.004. [Epub ahead of print]

PMID:
31153048
3.

A NOTCH added to metabolomics.

Brustugun OT.

Br J Cancer. 2019 Jul;121(1):3-4. doi: 10.1038/s41416-019-0463-0. Epub 2019 May 22.

PMID:
31114016
4.

The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.

Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å.

Mol Oncol. 2019 May;13(5):1166-1179. doi: 10.1002/1878-0261.12475. Epub 2019 Apr 10.

5.

Immune Cell Composition in Human Non-small Cell Lung Cancer.

Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A.

Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018.

6.

Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.

Brustugun OT, Grønberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland Å, Møller B, Nilssen Y, Strand TE, Solberg SK.

Lung Cancer. 2018 Aug;122:138-145. doi: 10.1016/j.lungcan.2018.06.003. Epub 2018 Jun 6.

PMID:
30032822
7.

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.

Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å.

BMC Cancer. 2018 Jul 13;18(1):739. doi: 10.1186/s12885-018-4659-0.

8.

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy.

Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å.

Adv Radiat Oncol. 2018 Feb 13;3(2):130-138. doi: 10.1016/j.adro.2017.12.007. eCollection 2018 Apr-Jun.

9.

Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab.

Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å.

Acta Oncol. 2018 Sep;57(9):1225-1231. doi: 10.1080/0284186X.2018.1465585. Epub 2018 Apr 23.

PMID:
29683761
10.

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.

Lund-Iversen M, Scott H, Strøm EH, Theiss N, Brustugun OT, Grønberg BH.

Anticancer Res. 2018 Apr;38(4):2261-2269.

PMID:
29599348
11.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK.

Nat Commun. 2018 Mar 13;9(1):1048. doi: 10.1038/s41467-018-03099-x.

12.

Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH.

Anticancer Res. 2018 Feb;38(2):871-876.

PMID:
29374714
13.

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.

J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27. Review.

14.

Cause-specific death after surgical resection for early-stage non-small-cell lung cancer.

Bugge AS, Lund MB, Valberg M, Brustugun OT, Solberg S, Kongerud J.

Eur J Cardiothorac Surg. 2018 Jan 1;53(1):221-227. doi: 10.1093/ejcts/ezx274.

PMID:
28950311
15.

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.

McGowan M, Kleinberg L, Halvorsen AR, Helland Å, Brustugun OT.

Genes Cancer. 2017 Mar;8(3-4):497-504. doi: 10.18632/genesandcancer.136.

16.

Implementation of lung cancer CT screening in the Nordic countries.

Pedersen JH, Sørensen JB, Saghir Z, Fløtten Ø, Brustugun OT, Ashraf H, Strand TE, Friesland S, Koyi H, Ek L, Nyrén S, Bergman P, Jekunen A, Nieminen EM, Gudbjartsson T.

Acta Oncol. 2017 Oct;56(10):1249-1257. doi: 10.1080/0284186X.2017.1329592. Epub 2017 Jun 1.

PMID:
28571524
17.

High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA.

Int J Cancer. 2017 Jul 1;141(1):184-190. doi: 10.1002/ijc.30726. Epub 2017 Apr 21.

18.

PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.

McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT.

Lung Cancer. 2017 Jan;103:52-57. doi: 10.1016/j.lungcan.2016.11.018. Epub 2016 Nov 28.

PMID:
28024696
19.

Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease.

Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å.

Clin Transl Immunology. 2016 Nov 2;5(11):e109. eCollection 2016 Nov.

20.

Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.

Halvorsen TO, Herje M, Levin N, Bremnes RM, Brustugun OT, Fløtten Ø, Kaasa S, Sundstrøm S, Grønberg BH.

Lung Cancer. 2016 Dec;102:9-14. doi: 10.1016/j.lungcan.2016.10.003. Epub 2016 Oct 15.

PMID:
27987595
21.

Real-world data on nivolumab treatment of non-small cell lung cancer.

Brustugun OT, Sprauten M, Helland Å.

Acta Oncol. 2017 Mar;56(3):438-440. doi: 10.1080/0284186X.2016.1253865. Epub 2016 Nov 28.

PMID:
27892773
22.

Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.

Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R, Peifer M, Helland A, Ball CR, Jechlinger M, Sotillo R, Glimm H, Korbel JO.

Nat Genet. 2017 Jan;49(1):65-74. doi: 10.1038/ng.3722. Epub 2016 Nov 21.

23.

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Nyman J, Hallqvist A, Lund JÅ, Brustugun OT, Bergman B, Bergström P, Friesland S, Lewensohn R, Holmberg E, Lax I.

Radiother Oncol. 2016 Oct;121(1):1-8. doi: 10.1016/j.radonc.2016.08.015. Epub 2016 Sep 3.

PMID:
27600155
24.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

25.

Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH.

Acta Oncol. 2016 Nov;55(11):1349-1354. Epub 2016 Aug 23.

PMID:
27549509
26.

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer.

Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM.

Diagn Pathol. 2016 Jun 17;11(1):50. doi: 10.1186/s13000-016-0504-4.

27.

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å.

Front Genet. 2016 May 11;7:85. doi: 10.3389/fgene.2016.00085. eCollection 2016.

28.

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer.

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å.

Oncotarget. 2016 Jun 14;7(24):37250-37259. doi: 10.18632/oncotarget.9363.

29.

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.

Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A.

F1000Res. 2016 Jan 8;5:38. doi: 10.12688/f1000research.7599.1. eCollection 2016.

30.

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes.

Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å.

BMC Cancer. 2016 Feb 8;16:71. doi: 10.1186/s12885-016-2104-9.

31.

Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.

Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å.

Mol Oncol. 2016 Feb;10(2):330-43. doi: 10.1016/j.molonc.2015.10.021. Epub 2015 Nov 6.

32.

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.

Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM.

Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16. Review.

PMID:
26578726
33.

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group.

Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23.

PMID:
26494411
34.

Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage.

Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Brustugun OT, O'Connell DL, Yu XQ, Møller B.

Int J Cancer. 2016 Mar 15;138(6):1350-60. doi: 10.1002/ijc.29875. Epub 2015 Oct 20. Erratum in: Int J Cancer. 2016 Aug 15;139(4):E4.

35.

NUT expression in primary lung tumours.

Lund-Iversen M, Grøholt KK, Helland Å, Borgen E, Brustugun OT.

Diagn Pathol. 2015 Sep 5;10:156. doi: 10.1186/s13000-015-0395-9.

36.

EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.

Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland Å.

Acta Oncol. 2016;55(2):149-55. doi: 10.3109/0284186X.2015.1062537. Epub 2015 Aug 26.

PMID:
26313507
37.

Comprehensive genomic profiles of small cell lung cancer.

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK.

Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

38.

[Typical growth pattern in malignant pleural mesothelioma].

Berg AS, Løndalen A, Brustugun OT.

Tidsskr Nor Laegeforen. 2015 Jun 16;135(11):1050. doi: 10.4045/tidsskr.14.0480. eCollection 2015 Jun 16. Norwegian. No abstract available.

39.

Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung.

Brustugun OT.

Semin Radiat Oncol. 2015 Apr;25(2):87-92. doi: 10.1016/j.semradonc.2014.11.006. Epub 2014 Nov 29. Review.

PMID:
25771412
40.

[Re: In momentous development?].

Brustugun OT.

Tidsskr Nor Laegeforen. 2015 Mar 10;135(5):413-4. doi: 10.4045/tidsskr.15.0208. eCollection 2015 Mar 10. Norwegian. No abstract available.

41.

Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.

Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT.

Clin Cancer Res. 2015 Jun 1;21(11):2635-43. doi: 10.1158/1078-0432.CCR-14-1905. Epub 2015 Feb 13.

42.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z, Solomon B, Petersen I, Clement JH, Sänger J, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Buettner R, Wolf J, Brambilla E, Vingron M, Perner S, Haas SA, Thomas RK.

Genome Biol. 2015 Jan 5;16:7. doi: 10.1186/s13059-014-0558-0.

43.

Years of life lost as a measure of cancer burden on a national level.

Brustugun OT, Møller B, Helland A.

Br J Cancer. 2014 Aug 26;111(5):1014-20. doi: 10.1038/bjc.2014.364. Epub 2014 Jul 1.

44.

[Time counts!].

Brustugun OT, Helland Å, Julsrud L.

Tidsskr Nor Laegeforen. 2014 May 13;134(9):915. doi: 10.4045/tidsskr.14.0057. eCollection 2014 May 13. Norwegian. No abstract available.

45.

[Re: Limited malignancy screening of patients with idiopathic venous thromboembolism].

Mynarek G, Aaløkken TM, Martinsen AC, Brustugun OT.

Tidsskr Nor Laegeforen. 2014 Apr 29;134(8):814-5. doi: 10.4045/tidsskr.14.0468. eCollection 2014 Apr 29. Norwegian. No abstract available.

46.

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.

Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly C, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK.

Nat Commun. 2014 Mar 27;5:3518. doi: 10.1038/ncomms4518.

47.

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas.

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A.

Int J Cancer. 2014 Oct 15;135(8):1812-21. doi: 10.1002/ijc.28828. Epub 2014 Mar 14.

48.

BRAF-mutations in non-small cell lung cancer.

Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å.

Lung Cancer. 2014 Apr;84(1):36-8. doi: 10.1016/j.lungcan.2014.01.023. Epub 2014 Feb 3.

PMID:
24552757
49.
50.

Human papilloma virus detection and typing in 334 lung cancer patients.

Sagerup CM, Nymoen DA, Halvorsen AR, Lund-Iversen M, Helland A, Brustugun OT.

Acta Oncol. 2014 Jul;53(7):952-7. doi: 10.3109/0284186X.2013.879608. Epub 2014 Jan 21.

PMID:
24446743

Supplemental Content

Loading ...
Support Center